Member Info for quercusrobor

https://www.zerohedge.com/health/remdesivir-probably-worthless-trauma-surgeon-exposes-drug-companys-shenanigans

testing

pls.....its just SO dull.....and as we all know....or should know...opinions are like a/holes.....we ALL have one....ty.

re....Investors here are doing likewise by building a strong holding as part of their balanced portfolio.

if ever there was a time to be totally unbalnced.......this surely has to be it!

https://news.sky.com/story/coronavirus-people-will-not-be-able-to-use-home-testing-kits-leading-gp-warns-11981898

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang, MD †
Dingyu Zhang, MD †
Prof Guanhua Du, PhD †
Prof Ronghui Du, MD †
Prof Jianping Zhao, MD †
Prof Yang Jin, MD †
et al.
Show all authors
Show footnotes

Published:April 29, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31022-9
PlumX Metrics
Previous ArticleRemdesivir for COVID-19: challenges of underpowe …

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

edit....header shld read....

The bloody future of international airport safety was just rolled out in Dubai

fyi...https://www.orlandoweekly.com/Blogs/archives/2020/04/24/the-bloody-future-of-international-airport-safety-was-just-rolled-out-in-dubai

yup....this looks like a 'world beater' for sure....what do you think? ;)

cont......

Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:

“What is so attractive about Avacta’s Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin.

Whilst immunotherapies offer great promise for cancer patients, it is well established that only a relatively small sub-group of patients see durable responses to single immune checkpoint therapies. Avacta is directly addressing this urgent clinical need with its novel Affimer TMAC and bispecific programmes.

The function of the linker in the TMAC is critical and I am delighted that the planned phase I study will allow us to test it well ahead of our original schedule. This is an important de-risking step for the TMAC programme and could be a catalyst for spin-off licensing opportunities for a range of chemotherapies with improved tolerability. The testing of an Affimer PD-L1 inhibitor, which will form part of the first full TMAC drug and be the foundation for bispecific Affimer immunotherapies, will be the subject of an IND application later in 2020.

It is a hugely exciting period for Avacta and I look forward to keeping the market updated on our progress.”

Dr Jose Saro MD, Chief Medical Officer, Avacta Group plc, commented:

“The TMAC linker is a key element of this ground breaking technology and we are excited to have the opportunity to test it in the clinic very soon. If successful, not only does it de-risk the TMAC platform, but it has the potential to significantly increase any chemotherapy therapeutic index allowing higher chemotherapy exposure in the tumour microenvironment to be maintained for a longer period with reduced systemic toxicity.

This could be one of the most important current advances in developing safer combinations of immunotherapies with chemotherapies and help Avacta to define a new Affimer-based standard of care in several solid tumours.”

1. hxxps://ukblaze.com/2019/05/01/latest-global-doxorubicin-market-report-2019-to-talk-about-historical-development-2014-2018-and-estimated-forecast-2019-2025/

2. hxxps://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014.

View source version on businesswire.com: hxxps://www.businesswire.com/news/home/20190603005367/en/

Zyme Communications
Katie Odgaard
Tel: +44 (0)7787 502 947
katie.odgaard@zymecommunications.com

Avacta Group plc TMAC Programme Accelerates: Clinical Trial Planned for Early 2020

Source: Business Wire
Key linker element of Avacta’s novel TMAC™ drug conjugate to be tested in humans within 12 months

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that it is planning to submit an IND/CTA application early in 2020 to test the TMAC™ linker in a phase I study in patients with selected solid tumours.

In an acceleration of the TMAC programme, Avacta is now in a position to test this critical TMAC linker in humans, a major de-risking milestone for the programme, early in 2020 and well ahead of its original plans.

Avacta’s tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy, co-invented with Tufts University Medical School, combining Affimers with chemotherapies in a single drug, using a linker that is designed to only release the chemotherapy in the tumour microenvironment. This allows extremely potent chemotherapies, too potent to be given to patients systemically, to be combined with Affimer immune-checkpoint therapies.

In order to test the TMAC linker in humans for the first time, a standard-of-care chemotherapy called doxorubicin has been modified with the linker rendering it inactive and harmless until the linker is cleaved in the tumour, releasing active doxorubicin. Doxorubicin has well documented safety issues limiting its dosing, and also limiting the patient sub-group that can be treated. Despite these issues, the global doxorubicin market is valued at $910m and is expected to reach $1.4bn by the end of 20251. Avacta’s TMAC linker has been shown to increase the maximum tolerated dose of doxorubicin by a factor of six in a pre-clinical study in mice.

Avacta plans to submit an IND/CTA application for a phase I clinical study of the TMAC linker-doxorubicin early in 2020. The phase I trial will comprise a dose escalation study in patients with selected solid tumours including advanced and metastatic high-grade soft tissue sarcoma. Successful functioning of the TMAC linker will be reflected in tumour shrinkage as a result of the release of doxorubicin. Potentially the study will also demonstrate improved tolerability over standard doxorubicin.

The cancer immunotherapy market is currently worth $60bn and is predicted to double by 20252. Avacta’s TMAC and bispecific cancer immunotherapies are designed not only to compete strongly in this market through improved clinical benefit to patients, but also to expand the market to patients who do not respond to single checkpoint inhibitors. Avacta has exclusive rights to commercialise TMAC drug conjugates.

Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:

“What is so attractive about Avacta’s Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same

Han**** says antigen home testing kits will be available very shortly.

re....This BB is a joke...should read...

This BB is....BEYOND... a joke.

re dusterhater Today 10:29 .will be like sng dropped 40% while placing shares clearing - sng back on the way up now - but gl but don't try to fool the novices please......

really.....placing of sng 25/26 March......perhaps this will illustrate your pointlessness....

Open High Low Close
Mar 30, 2020 50.70 63.00 48.00 62.00 11,360,657
Mar 27, 2020 45.00 48.00 44.00 46.00 4,268,185
Mar 26, 2020 47.50 49.00 42.30 45.00 4,317,705
Mar 25, 2020 50.11 55.50 37.20 46.50 10,185,243
Mar 24, 2020 50.40 57.00 43.00 51.50 8,006,427
Mar 23, 2020 51.95 69.00 49.00 49.00

why do you bother??...you really must be a rather ridiculous person.......

re..I think up coming placing has put the dampers on the rise a bit -

anyone get the feeling that the dilution % is being factored in as we 'speak'....

re...To clear this overhang before it takes off again.

Much to clear?

https://off-guardian.org/2020/04/17/8-more-experts-questioning-the-coronavirus-panic/

Wbernard..
A couple of questions for you,if I may be so bold...
1.Why your sudden 'vocal' interest in Avacta Plc ?
2.You appear to be expressing academically 'knowledgeable' opinions on a variety of Covid-19 and Avacta related topics.In order to sensibly give credence to your views,it would be more than useful if you be so kind as to let me (us) know what academic or other qualifications (Phd,Doctorates etc) in this field you have been awarded.
Tx

https://unherd.com/thepost/coming-up-epidemiologist-prof-johan-giesecke-shares-lessons-from-sweden/

Professor Johan Giesecke, one of the world’s most senior epidemiologists, advisor to the Swedish Government (he hired Anders Tegnell who is currently directing Swedish strategy), the first Chief Scientist of the European Centre for Disease Prevention and Control, and an advisor to the director general of the WHO, lays out with typically Swedish bluntness why he thinks:

UK policy on lockdown and other European countries are not evidence-based

The correct policy is to protect the old and the frail only

This will eventually lead to herd immunity as a “by-product”

The initial UK response, before the “180 degree U-turn”, was better

The Imperial College paper was “not very good” and he has never seen an unpublished paper have so much policy impact

The paper was very much too pessimistic

Any such models are a dubious basis for public policy anyway

The flattening of the curve is due to the most vulnerable dying first as much as the lockdown

The results will eventually be similar for all countries

Covid-19 is a “mild disease” and similar to the flu, and it was the novelty of the disease that scared people.

The actual fatality rate of Covid-19 is the region of 0.1%

At least 50% of the population of both the UK and Sweden will be shown to have already had the disease when mass antibody testing becomes available

A doctor has recorded the excruciating experience of a drive-through coronavirus test.

The video, filmed on April 15 in Oxford, shows Dr Rufus Cartwright retching as his nose and throat are swabbed in his first test for the virus, despite working on the front line of an NHS hospital.

The procedure causes him to wince and cough repeatedly on the tester showing how crucial PPE is to carrying out his work safely.

"I'm a doctor but I was really surprised how painful this was," Dr Cartwright said.

https://uk.news.yahoo.com/doc-records-excruciating-experience-drive-160000211.html

M.McNulty

Posts: 3

Price: 65.00

Strong Buy
Update noteToday 17:15

Hi all, hope everyone's well and enjoying the share price rise.

I've written an update note on #AVCT, focussing on its recently announced work on a point-of-care antigen test for #COVID19:

Thankyou v much indeed. V kind of you to share your knowledge and expertise.